Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy

Bioconjugate Chemistry

Volumn 15, Issue 6, 2004, Pages 1174-1181

  Patri, Anil K ^a   Myc, Andrzej ^a   Beals, James ^a   Thomas, Thommey P ^a   Bander, Neil H ^b   Baker Jr , James R ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODIES; ANTIGENS; DISEASES; TISSUE; UROLOGY;

CANCER CHEMOTHERAPEUTICS; CANCER THERAPY; CANCER TISSUES; IMMUNOCONJUGATE; IMMUNOREACTIVITIES; IN-VITRO TESTING; NORMAL TISSUE; POOR SOLUBILITIES; PROSTATE CANCERS; TARGETED THERAPEUTICS;

DENDRIMERS;

ANTIBODY CONJUGATE; DENDRIMER; DRUG CARRIER; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY J591; MONOCLONAL ANTIBODY PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

CONFERENCE PAPER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG BINDING; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG SOLUBILITY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; INTERNALIZATION; PROSTATE CANCER;

EID: 9244247342     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc0499127     Document Type: Conference Paper

References (30)

1. Guillemard, V., and Saragovi, H. U. (2001) Taxane-Antibody Conjugates Afford Potent Cytotoxicity, Enhanced Solubility, and Tumor Target Selectivity. Cancer Res. 61, 694-699.
2. Chang, S. S., Gaudin, P. B., Reuter, V. E., and Heston, W. D. W. (2000) Prostate-specific membrane antigen: Present and future application. Urology 55, 622-629.
3. Fair, W. R., Israeli, R. S., and Heston, W. D. W. (1997) Prostate-specific membrane antigen. Prostate 32, 140-148.
4. Chang, S. S., O'Keefe, D. S., Bacich, D. J., Reuter, V. E., Heston, W. D., and Gaudin, P. B. (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin. Cancer Res. 5, 2674-2681.
5. Liu, H., Moy, P., Kim, S., Xia, Y., Rajasekaran, A., Navarro, V., Knudsen, B., and Bander, N. H. (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57, 3629-3634.
6. Liu, H., Rajasekaran, A. K., Moy, P., Xia, Y., Kim, S., Navarro, V., Rahmati, R., and Bander, N. H. (1998) Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer Res. 58, 4055-4060.
7. Fracasso, G., Bellisola, G., Cingarlini, S., Castelletti, D., Prayer-Galetti, T., Pagano, F., Tridente, G., and Colombatti, M. (2002) Antitumor effects of toxins targeted to the prostate specific membrane antigen. Prostate 53, 9-23.
8. McDevitt, M. R., Barendswaard, E., Ma, D., Lai, L., Curcio, M. J., Sgouros, G., Ballangrud, A. M., Yang, W. H., Finn, R. D., Pellegrini, V., Geerlings, M. W., Jr., Lee, M., Brechbiel, M. W., Bander, N. H., Cordon-Cardo, C., and Scheinberg, D. A. (2000) An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res. 60, 6095-6100.
9. McDevitt, M. R., Ma, D., Lai, L. T., Simon, J., Borchardt, P., Frank, R. K., Wu, K., Pellegrini, V., Curcio, M. J., Miederer, M., Bander, N. H., and Scheinberg, D. A. (2001) Tumor therapy with targeted atomic nanogenerators. Science 294, 1537-1540.
10. Smith-Jones, P. M., Vallabahajosula, S., Goldsmith, S. J., Navarro, V., Hunter, C. J., Bastidas, D., and Bander, N. H. (2000) In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res. 60, 5237-5243.
11. Smith-Jones, P. M., Vallabhajosula, S., Navarro, V., Bastidas, D., Goldsmith, S. J., and Bander, N. H. (2003) Radio-labeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J. Nucl. Med. 44, 610-617.
12. Newkome, G. R., Moorefield, C. N., and Vogtle, F. (2001) Dendrimers and Dendrons: Concepts, Syntheses, Applications, Wiley-VCH, Weinheim, Germany.
13. Fréchet, J. M. J., and Tomalia, D. A. (2002) Dendrimers and other dendritic polymers, Wiley, Chichester, UK.
14. Patri, A. K., Majoros, I., and Baker, J. R., Jr. (2002) Dendritic polymer macromolecular carriers for drug delivery. Curr. Opin. Chem. Biol. 6, 466-471.
15. Cloninger, M. J. (2002) Biological applications of dendrimers. Curr. Opin. Chem. Biol. 8, 742-748.
16. Singh, P. (1998) Terminal groups in Starburst dendrimers: activation and reactions with proteins. Bioconjugate Chem. 9, 54-63.
17. Wu, C., Brechbiel, M. W., Kozak, R. W., and Gansow, O. A. (1994) Metal-chelate-dendrimer-antibody constructs for use in radioimmunotherapy and imaging. Bioorg. Med. Chem. Lett. 4, 449-454.
18. Kojima, C., Kono, K., Maruyama, K., and Takagishi, T. (2000) Synthesis of polyamidoamine dendrimers having poly-(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjugate Chem. 11, 910-917.
19. Esfand, R., and Tomalia, D. A. (2001) Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications. Drug Discovery Today 6, 427-436.
20. Quintana, A., Raczka, E., Piehler, L., Lee, L., Myc, A., Majoros, I., Patri, A. K., Thomas, T., Mule, J., and Baker, J. R., Jr. (2002) Design and function of a dendrimer-based therapeutic nanodevice targeted to tumor cells through the folate receptor. Pharm. Res. 19, 1310-1316.
21. Baker, J. R., Quintana, A., Piehler, L. T., Banazak-Holl, M., Tomalia, D., and Raczka, E. (2001) The synthesis and testing of anti-cancer therapeutic nanodevices. Biomed. Microdevices 3, 61-69.
22. Ong, K. K., Jenkins, A. L., Cheng, R., Tomalia, D. A., Durst, H. D., Jensen, J. L., Emanuel, P. A., Swim, C. R., and Yin, R. (2001) Dendrimer enhanced immunosensors for biological detection. Anal. Chim. Acta 444, 143-148.
23. Kobayashi, H., Sato, N., Saga, T., Nakamoto, Y., Ishimori, T., Toyama, S., Togashi, K., Konishi, J., and Brechbiel, M. W. (2000) Monoclonal antibody-dendrimer conjugates enable radiolabeling of antibody with markedly high specific activity with minimal loss of immunoreactivity. Eur. J. Nucl. Med. 27, 1334-1339.
24. Barth, R. F., Adams, D. M., Soloway, A. H., Alam, F., and Darby, M. V. (1994) Boronated Starburst Dendrimer-Monoclonal Antibody Immunoconjugates: Evaluation as a Potential Delivery System for Neutron Capture Therapy. Bioconjugate Chem. 5, 58-66.
25. Wu, G., Barth, R. F., Yang, W., Chatterjee, M., Tjarks, W., Ciesielski, M. J., and Fenstermaker, R. A. (2004) Site-specific conjugation of boron-containing dendrimers to anti-EGF receptor monoclonal antibody cetuximab (IMC-C225) and its evaluation as a potential delivery agent for neutron capture therapy. Bioconjugate Chem. 15, 185-194.
26. Roberts, J. C., Adams, Y. E., Tomalia, D. A., Mercer-Smith, J. A., and Lavallee, D. K. (1990) Using Starburst Dendrimers as Linker Molecules to Radiolabel Antibodies. Bioconjugate Chem. 1, 305-308.
27. Patri, A. K., Thomas, T., Baker, J. R., Jr. and Bander, N. H. (2002) Antibody-dendrimer conjugates for targeted prostate cancer therapy. Polym. Mater. Sci. Eng. 86, 130.
28. Chang, S. S., Reuter, V. E., Heston, W. D., Bander, N. H., Grauer, L. S., and Gaudin, P. B. (1999) Five different antiprostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res. 59, 3192-3198.
29. Hermanson, G. T. (1996) Heterobifunctional Cross-linkers, in Bioconjugate Techniques, pp 228-286, Elsevier Science, San Diego, CA.
30. Majoros, I. J., Keszler, B., Woehler, S., Bull, T., Baker, Jr., J. R. (2003) Acetylation of Poly(amidoamine) Dendrimers. Macromolecules 36, 5526-5529.